Papers

Peer-reviewed International journal
Mar, 2020

Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma.

Hepatology research : the official journal of the Japan Society of Hepatology
  • Teiji Kuzuya
  • ,
  • Masatoshi Ishigami
  • ,
  • Takanori Ito
  • ,
  • Yoji Ishizu
  • ,
  • Takashi Honda
  • ,
  • Tetsuya Ishikawa
  • ,
  • Mitsuhiro Fujishiro

Volume
50
Number
3
First page
374
Last page
381
Language
English
Publishing type
Research paper (scientific journal)
DOI
10.1111/hepr.13452

AIM: We aimed to investigate the radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma in real-world practice. METHODS: This retrospective study enrolled 40 patients who received lenvatinib. Radiological antitumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors. RESULTS: The objective response rate at 2 weeks and best overall response on confirmation of complete response, partial response (PR), and stable disease required (confirmed response) were 57.5% and 32.5%, respectively. Based on confirmed response, the overall survival rate was significantly longer in patients with an objective response rate than in those with stable disease or progressive disease after 12 months (73.2% and 54.2%, P = 0.0358). All 13 patients with an objective response rate on confirmed response were evaluated as PR at 2 weeks. The alpha-fetoprotein ratio at 2 weeks was a significant factor associated with PR of response rate at 2 weeks. The median relative dose intensity from 2 to 6 weeks was significantly lower than that from 0 to 2 weeks (69.6% vs. 100%, P < 0.0001). Stratified by the antitumor response at 6 weeks considering the image evaluation at 2 weeks, the median relative dose intensity from 2 to 6 weeks was significantly lower in patients with progressive disease than in those with PR or stable disease (45.2% vs. 72.6%, P = 0.0482). CONCLUSIONS: The radiological antitumor response at 2 weeks was favorable. Information on a favorable visible therapeutic response very early after lenvatinib initiation can help patients maintain their motivation for treatment, and allow physicians to continue treatment effectively and safely.

Link information
DOI
https://doi.org/10.1111/hepr.13452
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31721363
ID information
  • DOI : 10.1111/hepr.13452
  • Pubmed ID : 31721363

Export
BibTeX RIS